Free Trial

X4 Pharmaceuticals (XFOR) SEC Filings & 10K Form

X4 Pharmaceuticals logo
$1.82 -0.01 (-0.55%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.80 -0.02 (-1.04%)
As of 07/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent X4 Pharmaceuticals SEC Filings

DateFilerForm TypeView
07/18/2025
10:48 AM
BlackRock, Inc. (Filed by)
X4 Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
06/23/2025
3:34 PM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2025
7:12 AM
X4 Pharmaceuticals (Filer)
Form 424B5
06/10/2025
3:25 PM
WYZGA MICHAEL S (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025
3:28 PM
MCGIRR DAVID W J (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2025
5:12 PM
Thoren Natasha Fay (Reporting)
X4 Pharmaceuticals (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
05/20/2025
3:51 PM
Baldry Mark (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2025
8:22 AM
X4 Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/01/2025
5:25 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/25/2025
3:44 PM
X4 Pharmaceuticals (Filer)
Form DEF 14A
04/24/2025
7:57 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/26/2025
5:12 AM
X4 Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/25/2025
6:51 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2025
3:43 PM
X4 Pharmaceuticals (Filer)
Form DEF 14A
02/06/2025
3:06 PM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/31/2025
9:09 AM
VANGUARD GROUP INC (Filed by)
X4 Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
01/27/2025
5:15 PM
Arbet-Engels Christophe (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
Baldry Mark (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
Mostafa Adam S. (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2025
5:15 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2025
3:17 PM
Taveras Arthur (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/24/2025
3:18 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/24/2025
3:21 PM
Mostafa Adam S. (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/24/2025
3:22 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/16/2025
3:45 PM
X4 Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/13/2025
6:50 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
8:02 AM
X4 Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2024
7:11 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
5:12 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2024
1:15 PM
VANGUARD GROUP INC (Filed by)
X4 Pharmaceuticals (Subject)
Form SC 13G/A
10/22/2024
5:06 PM
BlackRock, Inc. (Filed by)
X4 Pharmaceuticals (Subject)
Form SC 13G
10/16/2024
3:54 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2024
3:07 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/08/2024
3:44 PM
Taveras Arthur (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
Ragan Paula (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
Baldry Mark (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/08/2024
3:44 PM
Mostafa Adam S. (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/04/2024
3:56 PM
X4 Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/11/2024
3:01 PM
DiBiase Mary (Reporting)
X4 Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
HIDDEN IN THE BOOK OF GENESIS… (Ad)

“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.

Watch Jim Rickards reveal the Old Testament Wealth Code
08/09/2024
3:28 PM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2024
5:40 AM
X4 Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:XFOR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners